Download PDF
Thromb Haemost 1990; 63(03): 482-487
DOI: 10.1055/s-0038-1645070
Original Article
Schattauer GmbH Stuttgart

Influence of Metoprolol Treatment on Sympatho-Adrenal Activation of Fibrinolysis

P T Larsson
1   The Department of Pharmacology, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
,
B Wiman
2   The Department of Clinical Chemistry, Karolinska Hospital, Stockholm, Sweden
,
G Olsson
3   The Department of Medicine, Danderyd Hospital and Metabolism Unit, Stockholm, Sweden
,
B Angelin
4   The Department of Medicine, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
,
P Hjemdahl
1   The Department of Pharmacology, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
5   Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 10 October 1989

Accepted after revision 19 February 1990

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effects of mental stress (a colour word conflict test, CWT) and adrenaline infusions (0.1 and 0.4 nmol kg−1 min−1) on t-PA activity, t-PA antigen, PAI-1 activity and PAI-1 antigen were studied in 18 healthy male volunteers. Furthermore, the effects of metoprolol (200 mg/day during 1 week) or placebo (double-blind cross-over study) on fibrinolytic responses to sympatho-adrenal activation, and relationships between fibrinolysis and blood lipids were investigated.

Low and high dose adrenaline infusions yielding plasma adrenaline levels of 0.9 ± 0.1 and 3.4 ± 0.4 nmol/1, respectively, dose-dependently increased t-PA levels with a concomitant decrease in PAI-1 levels. A similar, but weaker, fibrinolytic response seemed to occur during CWT when plasma adrenaline levels were only moderately increased (to 0.4 ± 0.1 nmol/1). Metoprolol treatment did not influence the resting levels of the fibrinolytic variables studied, but tended to enhance the t-PA response to CWT and further reduce PAI-1 during adrenaline infusion. Metoprolol treatment was not accompanied by any rise in PAI-1 levels despite drug induced elevations of triglyceride levels. Thus, the present study shows that sympatho-adrenal activation increases fibrinolytic activity in vivo and that meto prolol treatment may have a favourable influence on this activity.

 

  • References

  • 1 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63
    CrossrefPubMedGoogle Scholar
  • 2 Prowse CV, Cash JD. Physiologic and pharmacologic enhancement of fibrinolysis. Semin Thromb Hemostas 1984; 10: 51-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Gader AM A, Clarkson AR, Cash JD. The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline and salbutamol in man. Thromb Res 1973; 2: 9-16
    CrossrefPubMedGoogle Scholar
  • 4 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-36
    CrossrefPubMedGoogle Scholar
  • 5 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-5
    PubMedGoogle Scholar
  • 6 Urdén G, Hamsten A, Wiman B. Comparison of plasminogen activator inhibitor activity and antigen in plasma samples. Clin Chim Acta 1987; 169: 189-96
    CrossrefPubMedGoogle Scholar
  • 7 Himms-Hagen J. Sympathetic regulation of metabolism. Pharmacol Rev 1967; 19: 367-461
    PubMedGoogle Scholar
  • 8 Holtzman E, Rosenthal T, Goldbourt Ue, Segal P. Do Β-blockers alter lipids and what are the consequences. J Cardiovasc Pharmacol 1987; 10: S 86-92
    PubMedGoogle Scholar
  • 9 Roberts WC. Recent studies on the effect of beta blockers on blood lipid levels. Am Heart J 1989; 117: 709-14
    CrossrefPubMedGoogle Scholar
  • 10 Aberg H, Lithell H, Selinus I, Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Atherosclerosis 1985; 54: 89-97
    CrossrefPubMedGoogle Scholar
  • 11 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-8
    CrossrefPubMedGoogle Scholar
  • 12 Larsson PT, Hjemdahl P, Olsson G, Egberg N, Hornstra G. Altered platelet function during mental stress and adrenaline infusions in humans: evidence for an increased in vivo aggregability as measured by filtragometry. Clin Sci 1989; 76: 369-76
    CrossrefPubMedGoogle Scholar
  • 13 Frankenhaeuser M, Mellis I, Rissler A, Bjorkvall C, Patkai P. Catecholamine excretion as related to cognitive and emotional reaction patterns. Psychosom Med 1968; 30: 109-20
    CrossrefPubMedGoogle Scholar
  • 14 Hjemdahl P. Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 1987; 142: 521-34
    PubMedGoogle Scholar
  • 15 Henriksson P, Einarsson K, Eriksson A, Kelter U, Angelin B. Estrogen-induced gallstone disease in males. Studies on biliary lipid composition and gallstone formation during treatment of prostatic carcinoma. J Clin Invest 1989; 84: 811-6
    CrossrefPubMedGoogle Scholar
  • 16 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
    PubMedGoogle Scholar
  • 17 Kjaelgaard A, Kjaelgaard M. In vitro stimulation of plasminogen activator release from vein walls by adrenaline. J Clin Pathol 1986; 39: 1241-4
    CrossrefPubMedGoogle Scholar
  • 18 Conanan LB, Crutchley DJ. Serum-dependent induction of plasminogen activator in human fibroblasts by catecholamines and comparison with the effects of prostaglandin E1 . Biochim Biophvs Acta 1983; 759: 146-53
    CrossrefPubMedGoogle Scholar
  • 19 Wiman B, Chmielewska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-7
    PubMedGoogle Scholar
  • 20 Gader AM A, da Costa J, Cash JD. The effect of propranolol, alprenolol and practolol on the fibrinolytic and factor VIII responses to adrenaline and salbutamol in man. Thromb Res 1974; 4: 25-33
    PubMedGoogle Scholar
  • 21 Teger-Nilsson AC, Dahlöf C, Haglund E, Hedman C, Olsson G, Åblad B. Influence of metoprolol on plasminogen activator inhibitor (PAI-1) in man. J Clin Pharm 1990; 30: S 132-7
    CrossrefPubMedGoogle Scholar
  • 22 Rein E, Winther K. Beta blockade, tissue plasminogen activity and exercise. Thromb Haemostas 1989; 62: 536
    PubMedGoogle Scholar
  • 23 Grimaudo V, Hauert J, Bachmann F, Kruithof EK O. Diurnal variation of the fibrinolytic system. Thromb Haemostas 1988; 59: 495-9
    PubMedGoogle Scholar
  • 24 Kluft C, Jie AF H, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemostas 1988; 59: 329-32
    PubMedGoogle Scholar